Whitney & Co’s Haemonetics HAE Stock Holding History

Whitney & Co’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16	Closed	-$2K	–	249
2018 Q3	$2K	Buy	+16	New	+$1.66K	﹤0.01%	456

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Whitney & Co's HAE Position: Q4 2018 in Review

Whitney & Co sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 16 shares — an estimated $2K sold.

Whitney & Co first reported a position in HAE in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

Whitney & Co reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 16 Haemonetics shares in Q4 2018, an estimated $2K.
Whitney & Co first reported a position in Haemonetics in Q3 2018 and held it in 1 quarter.
Whitney & Co's Haemonetics position peaked at $2K in Q3 2018.
279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.